Page last updated: 2024-08-24

lurtotecan and Neoplasms

lurtotecan has been researched along with Neoplasms in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (58.33)	18.2507
2000's	5 (41.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bailly, C; Lansiaux, A	1
Eisenhauer, E; Fisher, B; Gelmon, K; Hirte, HW; MacKenzie, MJ; Ptaszynski, M; Siu, LL	1
Eisenhauer, E; Fisher, B; Gelmon, K; Hamilton, M; Hirte, H; Onetto, N; Ptaszynski, M; Walsh, W	1
Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Kunka, R; Marijnen, Y; Planting, AS; Schellens, JH; Selinger, K; Verweij, J; Wissel, P	1
Aureche, C; Depee, S; Selinger, K; Smith, G	1
Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P	1
de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J	1
Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P	1
Alden, M; Beranek, P; Cassidy, J; DeMaria, D; Depee, S; Kaye, S; Kunka, R; Littlefield, D; O'Dwyer, P; Paz-Ares, L; Reilly, D; Twelves, C; Wissel, P	1
DeMaria, D; Grochow, LB; Kaye, SB; McDonald, A; O'Dwyer, PJ; Paz-Ares, L; Selinger, K; Sludden, J; Stevenson, JP; Twelves, C; Wissel, P	1
Abbott, EA; Bendele, RA; Brown, EN; Desjardins, JP; Dihel, L; Emerson, DL; Hamilton, M; Leray, JD; Ptaszynski, M; Richardson, FC; Tomkinson, BE	1
Calvert, H; Cortes-Funes, H; Dombernowsky, P; Gamucci, T; Gore, ME; Hanauske, AR; Heinrich, B; Kaye, SB; Lehnert, M; Loos, WJ; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Selinger, K; Sessa, C; van Oosterom, AT; Verweij, J; Wanders, J; Wissel, PS	1

Reviews

1 review(s) available for lurtotecan and Neoplasms

Article	Year
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997

Trials

9 trial(s) available for lurtotecan and Neoplasms

Article	Year
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome	2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors	2004
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. British journal of cancer, 1996, Volume: 73, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors	1996
Determination of GI147211 in human blood by HPLC with fluorescence detection. Journal of pharmaceutical and biomedical analysis, 1995, Volume: 13, Issue:12 Topics: Antineoplastic Agents; Biotransformation; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Humans; Hydrolysis; Infusions, Intravenous; Neoplasms; Reference Standards; Spectrometry, Fluorescence	1995
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting	1997
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British journal of cancer, 1998, Volume: 78, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors	1998
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome	1999
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sampling Studies; Topoisomerase I Inhibitors	2002

Other Studies

2 other study(ies) available for lurtotecan and Neoplasms

Article	Year
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Neoplasms; Tissue Distribution	2001